[
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System",
    "summary": "Abbott Laboratories (NYSE:ABT) recently received FDA approval for its Tendyne™ TMVR system, a significant milestone enhancing its cardiovascular product portfolio. Over the past month, Abbott's stock price moved up by about 3%, which aligns with broader market trends, suggesting that its advancements may have supported this momentum. Alongside this, updates on partnerships and product innovations, such as integrating glucose monitoring data with Epic's health records and collaborating with...",
    "url": "https://finnhub.io/api/news?id=3c7ade23a621b8c025157d72c799048d703ff22e5064688b5a6c3927ffd6fe1f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748453035,
      "headline": "Abbott Laboratories (NYSE:ABT) Gains FDA Nod For Tendyne Mitral Valve System",
      "id": 134755874,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) recently received FDA approval for its Tendyne™ TMVR system, a significant milestone enhancing its cardiovascular product portfolio. Over the past month, Abbott's stock price moved up by about 3%, which aligns with broader market trends, suggesting that its advancements may have supported this momentum. Alongside this, updates on partnerships and product innovations, such as integrating glucose monitoring data with Epic's health records and collaborating with...",
      "url": "https://finnhub.io/api/news?id=3c7ade23a621b8c025157d72c799048d703ff22e5064688b5a6c3927ffd6fe1f"
    }
  },
  {
    "ts": null,
    "headline": "How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott",
    "summary": "Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.",
    "url": "https://finnhub.io/api/news?id=32141cf23be664a182690e3fbf292fe2ab7bf3ba8221a4755afad3b5502496b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748441680,
      "headline": "How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott",
      "id": 134742017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.",
      "url": "https://finnhub.io/api/news?id=32141cf23be664a182690e3fbf292fe2ab7bf3ba8221a4755afad3b5502496b1"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Stock Gains Following FDA Approval of the Tendyne System",
    "summary": "ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.",
    "url": "https://finnhub.io/api/news?id=261a6b0de4fa7c43764f95cc55133b7b8b717bca90abd5cb32d7bf9e2341bb6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748438520,
      "headline": "Abbott Stock Gains Following FDA Approval of the Tendyne System",
      "id": 134755875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.",
      "url": "https://finnhub.io/api/news?id=261a6b0de4fa7c43764f95cc55133b7b8b717bca90abd5cb32d7bf9e2341bb6f"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T",
    "summary": "Coca-Cola, Abbott and AT&T shine in Zacks' latest reports, with each outperforming peers year-to-date despite headwinds in key segments.",
    "url": "https://finnhub.io/api/news?id=69cee56e51a8f984ea6dee45526dd6ac37eaedc6f91852421e75578480cf09f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748425860,
      "headline": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories and AT&T",
      "id": 134741980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Coca-Cola, Abbott and AT&T shine in Zacks' latest reports, with each outperforming peers year-to-date despite headwinds in key segments.",
      "url": "https://finnhub.io/api/news?id=69cee56e51a8f984ea6dee45526dd6ac37eaedc6f91852421e75578480cf09f1"
    }
  },
  {
    "ts": null,
    "headline": "Carillon Eagle Growth & Income Fund Q1 2025 Commentary",
    "summary": "The S&P 500 Index concluded the first quarter down 4.3%, marking a turbulent start to 2025 following two years of robust gains.",
    "url": "https://finnhub.io/api/news?id=d50e1aa95264fc5360842dad0869e6d58bbfd215a3ed2d2d46118ac2a01bcb00",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748421720,
      "headline": "Carillon Eagle Growth & Income Fund Q1 2025 Commentary",
      "id": 134741260,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190009797/image_2190009797.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "The S&P 500 Index concluded the first quarter down 4.3%, marking a turbulent start to 2025 following two years of robust gains.",
      "url": "https://finnhub.io/api/news?id=d50e1aa95264fc5360842dad0869e6d58bbfd215a3ed2d2d46118ac2a01bcb00"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio",
    "summary": "Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, the first device of its kind approved in the US to treat mitral valve disease without open-heart surgery. Tendyne is specifically designed for patients who are not suitable candidates for surgical valve repair or replacement. The product perfectly […]",
    "url": "https://finnhub.io/api/news?id=eb3d969ad8501088a0fc2b74e244a84cb747cd28796e3ae484d82eccd9f73443",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748393926,
      "headline": "Abbott Gains FDA Approval for Tendyne™, Strengthening Its Minimally Invasive Heart Portfolio",
      "id": 134742019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) has received FDA approval today for its Tendyne™ transcatheter mitral valve replacement (TMVR) system, the first device of its kind approved in the US to treat mitral valve disease without open-heart surgery. Tendyne is specifically designed for patients who are not suitable candidates for surgical valve repair or replacement. The product perfectly […]",
      "url": "https://finnhub.io/api/news?id=eb3d969ad8501088a0fc2b74e244a84cb747cd28796e3ae484d82eccd9f73443"
    }
  }
]